Advertisement
UK markets close in 5 hours 18 minutes
  • FTSE 100

    8,296.18
    +82.69 (+1.01%)
     
  • FTSE 250

    20,388.36
    +223.82 (+1.11%)
     
  • AIM

    777.17
    +5.64 (+0.73%)
     
  • GBP/EUR

    1.1645
    -0.0014 (-0.12%)
     
  • GBP/USD

    1.2533
    -0.0030 (-0.24%)
     
  • Bitcoin GBP

    51,124.12
    -928.65 (-1.78%)
     
  • CMC Crypto 200

    1,329.78
    -35.34 (-2.59%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • DOW

    38,852.27
    +176.59 (+0.46%)
     
  • CRUDE OIL

    78.31
    -0.17 (-0.22%)
     
  • GOLD FUTURES

    2,321.50
    -9.70 (-0.42%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     
  • DAX

    18,292.35
    +117.14 (+0.64%)
     
  • CAC 40

    8,022.53
    +25.89 (+0.32%)
     

Ardelyx kidney drug meets main goal in mid-stage study

Feb 2 (Reuters) - Ardelyx Inc (NasdaqGM: ARDX - news) said its experimental drug significantly decreased phosphate levels in chronic kidney disease patients who were on dialysis.

The drug, being co-developed with AstraZeneca PLC (NYSE: AZN - news) , however, led to patients in the mid-stage study having a higher-than-expected rate of diarrhea. (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Savio D'Souza)